| Risperdal Consta (risperidone depot formulation) / J&J |
NCT00253136: A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia |
|
|
| Completed | 3 | 458 | US | risperidone | Janssen, LP | Schizophrenia, Psychotic Disorders | | 12/00 | | |
NCT00249223: A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia |
|
|
| Completed | 3 | 641 | Europe | Risperidone Long acting injectable | Janssen Pharmaceutica N.V., Belgium | Schizophrenia, Psychotic Disorders | | 12/00 | | |
NCT00034775: A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia. |
|
|
| Completed | 3 | 141 | US | risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia, Psychotic Disorders | | 10/02 | | |
NCT00236457: A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 3 | 629 | US | risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia, Psychotic Disorders | | 12/02 | | |
NCT00236548: Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection |
|
|
| Completed | 3 | 1 | US | risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen, LP | Schizophrenia, Psychotic Disorders | | 01/03 | | |
NCT00236353: Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 3 | 86 | US | risperidone | Janssen, LP | Schizophrenia, Psychotic Disorders | | 12/03 | | |
NCT00210691: A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 3 | 273 | US | Risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 02/04 | | |
NCT00236587: A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia |
|
|
| Completed | 3 | 100 | US | risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 02/04 | | |
NCT00297388: A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 3 | 40 | US | Risperidone, long-acting injectable | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen, LP | Schizophrenia, Schizoaffective Disorder | | 09/04 | | |
NCT00558298: A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder. |
|
|
| Completed | 3 | 811 | US | risperidone | Janssen, LP | Schizophrenia, Schizoaffective Disorder | | 02/05 | | |
NCT00495118: A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients. |
|
|
| Completed | 3 | 314 | US | risperidone | Janssen, LP | Schizophrenia, Schizoaffective Disorder | | 03/05 | | |
NCT00148083: Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia |
|
|
| Completed | 3 | 5 | US | Risperdal Consta (drug), Social Skills Training | University of Illinois at Chicago, Janssen, LP, Weill Medical College of Cornell University | Schizophrenia, Schizoaffective Disorder | 03/06 | 03/06 | | |
NCT00246246: A Randomized, Open-label Trial of Long-acting Injectable Risperidone Versus Oral Antipsychotic Medication in Patients With Bipolar Disorder |
|
|
| Completed | 3 | 48 | US | risperidone | Janssen-Ortho Inc., Canada | Bipolar Disorder | | 04/06 | | |
NCT00828958: Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients. |
|
|
| Completed | 3 | 53 | US | Risperidone long-acting injectable | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 09/06 | | |
NCT00094926: A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes. |
|
|
| Completed | 3 | 275 | US | Risperdal Consta, placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen, LP | Bipolar Disorder | | 02/07 | | |
NCT00210717: A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia |
|
|
| Completed | 3 | 748 | US | paliperidone palmitate | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 04/07 | | |
| Completed | 3 | 559 | US, Europe, RoW | Risperdal Consta, Placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Bipolar Disorder | 10/07 | 12/07 | | |
NCT00216476: A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 3 | 753 | Europe, RoW | Aripiprazole, Risperidone Long Acting Injectable (LAI), Quetiapine | Janssen-Cilag International NV | Schizophrenia, Psychotic Disorders | 11/07 | 11/07 | | |
| Completed | 3 | 50 | US | Injectable Risperidone (Consta) or oral antipsychotic, Long actiing risperidone injection (Consta), oral risperidone (risperdal)., Olanzapine (Zyprexa), Quetiapine (Seroquel), Ziprasidone (Geodon), Aripiprazole (Ablify) | University of Pittsburgh, Janssen Pharmaceuticals | Bipolar I Disorder | 03/08 | 12/09 | | |
NCT00391222: A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder |
|
|
| Completed | 3 | 585 | Europe, RoW | Olanzapine, Placebo, Risperidone Long Acting Injectable (LAI) | Janssen Pharmaceutica N.V., Belgium | Bipolar Disorder | 04/09 | 04/09 | | |
NCT00589914: Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia |
|
|
| Completed | 3 | 1221 | US, Europe, RoW | RISPERDAL CONSTA, Paliperidone palmitate | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 06/09 | 06/09 | | |
2004-002694-22: A Randomized, Double-Blind, Parallel Group Non-inferiority Study of Flexibly Dosed Paliperidone Palmitate(25, 50, 75, 100 mg eq) Administered Every 4 weeks and Flexibly Dosed Risperdal Consta (25, 37.5, 50 mg) Administered Every 2 weeks in Subjects with Schizophrenia |
|
|
| | 3 | 96 | Europe | Paliperidone Palmitate 25 mg, Paliperidone Palmitate 50 mg, Paliperidone Palmitate 75 mg, Paliperidone Palmitate 100 mg, Risperdal CONSTA 25mg, Risperdal CONSTA 37.5 mg, Risperdal CONSTA 50 mg, Risperdal 1mg Tablets, F5, Risperdal CONSTA, Risperdal, Risperdal CONSTA, Risperdal | Janssen-Cilag International N.V, Janssen-Cilag International NV, JANSSEN-CILAG International N.V., Janssen-Cilag International N.V., Janssen-Cilag, S.A. | schizophrenia | | 04/07 | | |
2006-003560-62: A Randomized, Double-Blind, Parallel-Group, Comparative Study of FlexibleDoses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-ActingIntramuscular Injection in Subjects with Schizophrenia |
|
|
| | 3 | 90 | Europe | Paliperidone OROS 6mg extended release (ER) system, Paliperidone Palmitate 100mg/ml nano suspension, Risperdal 1mg Tablets, Risperdal CONSTA 25mg, Risperdal Consta 37.5mg, Risperidone CONSTA 50 mg, F040, R092670 (F013), F005, F109, INVEGA, INVEGA | Janssen-Cilag International N.V., Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium, Janssen-Cilag International N.V., Turnhoutseweg 30, 2340 Beerse, Belgium | Schizophrenia | | 06/09 | | |
2006-001490-15: A randomized, double-blind, placebo- and active-controlled, parallel-group study to evaluate the efficacy and safety of risperidone long-acting injectable for theprevention of mood episodes in the treatment of subjects with bipolar I disorder |
|
|
| Completed | 3 | 32 | Europe | Risperdal 1 mg, Risperdal Consta/25 mg, Olanzapine, Risperdal Consta/37,5 mg, Risperdal Consta/50 mg, F005, F109, F292, Risperdal, Risperdal CONSTA, Zyprexa, Risperdal, Risperdal CONSTA, Zyprexa | Janssen-Cilag International N.V | Subjects with a diagnosos of bipolar I disorder who are currently experiencing a manic or mixed episode (YMRS>20 and CGI-S>/= 4 [moderate]) or who are between mood episodes (non-acute; YMRS<12 and CGI-S | | 04/09 | | |
| Ongoing | 3 | 250 | RoW | LY03004, RISPERDAL® CONSTA®, TEST, REFERENCE, Powder and solvent for prolonged-release suspension for injection, EU Risperdal® Consta® | Nanjing Luye Pharmaceutical Co., Ltd., Nanjing Luye Pharmaceutical Co., Ltd., Luye Pharma Group, Ltd. | schizophrenia, schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
